This inventor holds 1 USPTO granted patent. Top assignee: Ludwig Institute for Cancer Research Limited. Active years: 2002.
Company Filing History:
Years Active: 2002
Title: Michael Derek Warerfield: Innovator in Lipid Kinase Research
Introduction: Michael Derek Warerfield is a notable inventor based in London, GB. He has made significant contributions to the field of biochemistry, particularly in the study of lipid kinases. His work has implications for cancer research and treatment.
Latest Patents: Warerfield holds a patent for a novel human class II PI3-kinase, specifically termed PI3K-C2α. This invention relates to the sequence of the isolated nucleic acid molecule and the encoded amino acid sequence. The unique biochemical properties of this novel human PI3-kinase distinguish it from known PI3-kinases. These properties include resistance to the PI3-kinase inhibitors Wortmannin and LY294000, the absence of a p85 binding site, a divergent amino terminus, and the lack of a polyproline motif typical of known type II PI3-kinases. He has 1 patent to his name.
Career Highlights: Warerfield is associated with the Ludwig Institute for Cancer Research Limited, where he conducts his research. His work focuses on understanding the mechanisms of lipid kinases and their role in cancer biology.
Collaborations: One of his notable collaborators is Jan Domin, with whom he has worked on various research projects.
Conclusion: Michael Derek Warerfield's innovative research in lipid kinases represents a significant advancement in biochemistry and cancer research. His contributions continue to influence the scientific community and pave the way for future discoveries.